Revenues for the Third Quarter of 2017: Continued Growth for the Xposition S Stent

- Quarterly sales of the Xposition S stent up +19% in volume
- Third quarter revenues: €1.6 million (-4.7%)

PARIS - October 12, 2017 - 5.45 pm (CEST) – STENTYS (FR0010949404 – STNT), a medical technology company commercializing the Xposition S self-apposing coronary stent, today reports its revenues for the third quarter and first nine months of 2017.

Change in revenues

<table>
<thead>
<tr>
<th></th>
<th>€ thousands</th>
<th></th>
<th>% change</th>
<th>€ thousands</th>
<th></th>
<th>% change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues*</td>
<td>5,162.40</td>
<td>5,337.90</td>
<td>-3.2%</td>
<td>1,614.80</td>
<td>1,693.50</td>
<td>-4.7%</td>
</tr>
</tbody>
</table>

* Unaudited data

During the third quarter of 2017, STENTYS recorded revenues of €1.6 million, down 4.7% compared to the same period of 2016. This slight decrease is linked to the end of the commercialization of previous-generation stents (SES / PES), which could not be entirely offset despite a sound increase in sales of the Xposition S stent (+19% in volume and +4% in value). The self-apposing Sirolimus-eluting stent now accounts for 90% of the Company’s total revenues, as of September 30, 2017.

Over the first nine months of 2017, sales totaled €5.2 million, down 3.2% compared to the first nine months of 2016.

Christophe Lottin, Chief Executive Officer of STENTYS, comments: “During the third quarter, we have continued our efforts to rationalize our offer, which is now primarily based on our flagship product, the Xposition S stent. The continuous growth in sales since its launch confirms its added value compared to conventional stents. We are intensively working to accelerate its adoption in strategic countries through a specific training program devoted to new users, while pursuing its regulatory approval in new countries in order to stimulate our growth from 2018.”

About STENTYS

STENTYS develops and commercializes innovative solutions for the treatment of patients with complex artery disease. STENTYS’ Self-Apposing drug-eluting stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials for the treatment of acute myocardial infarction showed a very low mortality rate at one year and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS’ commercial network in Europe, the Middle East, Asia and Latin America.

Additional information is available at www.stentys.com

STENTYS
André Lerebours
CFO
Tel.: +33 (0)1 44 53 99 42
investor@stentys.com

NewCap
Investor Relations / Strategic Communications
Dusan Oresansky / Alexia Faure
Tel.: +33 (0)1 44 71 94 92
stentys@newcap.eu

STENTYS is listed on Compartment C of Euronext Paris
ISIN: FR0010949404 – Ticker: STNT
Safe Harbor Statements
This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2015 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers (AMF) on August 30, 2016 under number D.16-804.